Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin

American Journal of Gastroenterology

Volumn 106, Issue 7, 2011, Pages 1246-1254

  De Rueda, Paloma Mũoz ^a,b   López Nevot, Miguel Ngel ^c   Sáenz López, Pablo ^c   Casado, Jorge ^a   Martín Casares, Antonia ^c   Palomares, Pablo ^a   Quiles, Rosa ^a,b   Gila, Ana ^a,b   Romero Gómez, Manuel ^b,d   Pavón, Esther José ^a   Mũoz, José Antonio ^a   Carazo, Ángel ^a   Sanz Cameno, Paloma ^b,e   Moreno Otero, Ricardo ^b,e   Diago, Moisés ^f   León, Josefa ^a,b   Ruiz Extremera, Ángeles ^a,b   Salmerón, Javier ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; HLA DQB1 ANTIGEN; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ALLELES; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG THERAPY, COMBINATION; FEMALE; GENES, MHC CLASS I; GENES, MHC CLASS II; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERLEUKINS; LOGISTIC MODELS; MALE; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; ROC CURVE; VIRAL LOAD;

EID: 79960035861     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.82     Document Type: Article

References (31)

1. Poynard T, Yuen MF, Ratziu V et al. Viral hepatitis C. Lancet 2003; 362: 2095-100. (Pubitemid 38035201)
2. Salmer ó n J, Mu ñ oz De Rueda P, Ruiz-Extremera A et al. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. Digest Dis Sci 2006; 51: 960-7. (Pubitemid 44030823)
3. Salmer ó n J, Casado J, Mu ñ oz De Rueda P et al. Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype-1, treated with peginterferon- ribavirin. J Clin Virol 2008; 41: 264-9.
4. Mu ñoz De Rueda P, Paton R, Casado J et al. Prospective studies of mutations in the E2-PePHD, NS5A-PKRBD, NS5A-ISDR and NS5A-V3 regions of hepatitis C virus genotype-1 and their relationship to peginterferon and ribavirin treatment response. J Virol 2008; 82: 6644-53. (Pubitemid 351875141)
5. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49: 634-51.
6. Feld JJ, Hoofnaglr JH. Mechanism of action of interferon and RBV in treatment of hepatitis C. Nature 2005; 436: 967-72. (Pubitemid 41191673)
7. Folgori A, Spada E, Pezzanera M et al. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut 2006; 55: 1012-9. (Pubitemid 43962615)
8. Hong X, Yu RB, Sun NX et al. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005; 11: 7302-7. (Pubitemid 43137680)
9. Singh R, Kaul R, Kaul A et al. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007; 13: 1770-87. (Pubitemid 46706009)
10. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237-45. (Pubitemid 38967177)
11. Rhodes SL, Erlich H, Im KA et al. Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection. Genes Immun 2008; 9: 328-33. (Pubitemid 351791488)
12. Yee LJ, Im K, Wahed AS et al. Polymorphism in the human major histocompatibility complex and early viral decline during treatment of chronic hepatitis C. Antimicrob Agents Chemother 2009; 53: 615-21.
13. Dai CY, Chuang WL, Hsieh MY et al. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients. Antiviral Res 2010; 85: 396-402.
14. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 46: 399-401.
15. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
16. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8. (Pubitemid 36104710)
17. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons α and λinhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98. (Pubitemid 44958521)
18. Dellgren C, Gad HH, Hamming OJ et al. Human interferon-l3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-31.
19. Caballero T, P é rez-Milena A, Masseroli M et al. Liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001; 34: 740-7. (Pubitemid 32488790)
20. Shiff man ML, Suter F, Bacon BR et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34. (Pubitemid 47057730)
21. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa- 2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
22. Kamal SM, El Tawil AA, Nakano T et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-66. (Pubitemid 40732106)
23. Jacobson IM, Brown RS Jr, Freilich B et al. Peginterferon alfa-2b and weight-based or flatdose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971-81. (Pubitemid 350144761)
24. Rosen HR, Weston SJ, Im K et al. Selective decrease in hepatitis C virusspecific immunity among African Americans and outcome of antiviral therapy. Hepatology 2007; 46: 350-8. (Pubitemid 47344769)
25. Golden-Mason L, Klarquist J, Wahed AS et al. PD-1 expression is increased on immunocytes in chronic HCV and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008; 180: 3637-41.
26. Lamonaca V, Missale G, Urbani S et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology 1999; 30: 1088-98. (Pubitemid 29458301)
27. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
28. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
29. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010; 138: 2307-14.
30. Rauch A, Kutalik Z, Descombes P et al. Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45.
31. Pietilä TE, Latvala S, Osterlund P et al. Inhibition of dynamin-dependent endocytosis interferes with type III IFN expression in bacteria-infected human monocyte-derived DCs. J Leukoc Biol 2010; 88: 665-74.